This grant is designed to support research into how certain drugs, known as incretin mimetics, affect cancer risk. These drugs are typically used for conditions like diabetes and weight loss, but this grant focuses on understanding their long-term impact on cancer. The goal is to encourage studies that explore the biological mechanisms behind these effects.
Who it's for: This grant is open to a wide range of applicants, including nonprofits, government entities, small businesses, and educational institutions. Researchers and scientists with expertise in studying the effects of incretin mimetics on cancer risk are particularly encouraged to apply.
More details
Likely Disqualifiers
- Proposing a clinical trial
- Not focusing on cancer risk mechanisms
- Lack of expertise in incretin mimetics
- Ineligible organization type
What You May Need
- Detailed research proposal
- Budget plan
- Organizational eligibility documentation
- Research team bios
- Past research experience documentation
- Letters of support or collaboration
- Institutional Review Board (IRB) approval
- Data management plan
Cautions
- Clinical trials are not allowed
- Focus must be on cancer risk, not other outcomes
- Ensure all eligibility criteria are met
Generated from official source details for readability
Eligibility
Eligible Applicant Types
Additional Criteria
This grant is open to a wide range of applicants, including nonprofits, government entities, small businesses, and educational institutions. Researchers and scientists with expertise in studying the effects of incretin mimetics on cancer risk are particularly encouraged to apply.
Overview
This grant is open to a wide range of applicants, including nonprofits, government entities, small businesses, and educational institutions. Researchers and scientists with expertise in studying the effects of incretin mimetics on cancer risk are particularly encouraged to apply.
Likely Disqualifiers
- Proposing a clinical trial
- Not focusing on cancer risk mechanisms
- Lack of expertise in incretin mimetics
- Ineligible organization type
Use of Funds
Funds can be used to conduct preclinical and patient-based studies that investigate how incretin mimetics influence cancer risk. This includes costs related to research personnel, equipment, and necessary materials.
Cost Sharing
Not Required
Important Dates
- Posted
- Nov 18, 2024
- Deadline
- Jan 7, 2027(208 days)
- Archive Date
- Feb 12, 2027
- Last Updated
- Nov 18, 2024
- Est. Award Date (AI estimate)
- Spring 2027
Application Checklist
- Verify organizational eligibility
- Develop a research proposal focused on cancer risk mechanisms
- Prepare a detailed budget plan
- Gather bios and past research documentation for the research team
- Obtain letters of support or collaboration
- Secure Institutional Review Board (IRB) approval if applicable
- Create a data management plan
- Submit application by January 7, 2027